Search Results - "Haley, Ann Cameron"

Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia by Reid, Erika Elise, BA, Haley, Ann Cameron, BA, Borovicka, Judy H., MD, Rademaker, Alfred, PhD, West, Dennis P., PhD, Colavincenzo, Maria, MD, Wickless, Heather, MD

“…Background Hair loss may significantly impact an individual’s self-image, and studies indicate that patients with both clinically apparent and clinically…”
Get full text

Skin care management in cancer patients: an evaluation of quality of life and tolerability by Haley, Ann Cameron, Calahan, Cara, Gandhi, Mona, West, Dennis P., Rademaker, Alfred, Lacouture, Mario E.

“…Purpose The objective of this study is to evaluate quality of life (QoL) and tolerability of three articles specifically developed for cancer skin care…”
Get full text

Melanoma trainer using simulated back skin: an innovative design by MacGregor, Caitlin A, O'Donnell, Mary K, Haley, Ann Cameron, Martini, Mary, Robinson, June K, Vozenilek, John A

“…The method used to create a melanoma trainer using simulated back skin is presented. The trainer is intended to be used to teach medical students to identify…”
Get full text

Melanoma opportunistic surveillance by physician assistant and medical students: analysis of a novel educational trainer by Haley, Ann Cameron, MacLean, Michael, Bierman, Jennifer, Martini, Mary C, Vozenilek, John, Kwasny, Mary J, McGaghie, William C, Robinson, June K

“…The objective was to identify first-year physician assistant (PA) students' and third-year medical students' knowledge, attitudes, and behaviors about melanoma…”
Get full text

Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents by Borovicka, Judy H, Calahan, Cara, Gandhi, Mona, Abraham, Tara S, Kwasny, Mary J, Haley, Ann Cameron, West, Dennis P, Lacouture, Mario E

“…To report the financial impact of diagnosing and treating the dermatologic toxicities (dTs) that develop in patients receiving targeted anticancer therapies…”
Get more information